BioScrip (BIOS) Misses Q4 EPS by 11c

BioScrip (NASDAQ: BIOS) reported Q4 EPS of ($0.14), $0.11 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $183.6 million versus the consensus estimate of $188.41 million.

For earnings history and earnings-related data on BioScrip (BIOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform